Upperton Completes £15M GMP Manufacturing Facility

Xin Weisheng

Home > News > INDUSTRY NEWS >

12 Jul 2023
Upperton Completes £15M GMP Manufacturing Facility

Upperton Pharma Solutions, a CDMO, has completed construction of its development and GMP manufacturing headquarters in Nottingham, UK.


Located less than two miles from Upperton’s current headquarters, the facility houses ten new GMP manufacturing suites, quality control laboratories, and formulation development with pilot plant capabilities.


The new site increases the Upperton manufacturing footprint to 13,000 sq.-ft, and significantly expands analytical laboratory space, from 880 sq.-ft. to 8,500 sq.-ft. It has the capability to handle highly potent and controlled drugs in a range of dosage forms and support early formulation development, clinical trial supplies from Phase 1 to Phase 3, and niche-scale commercial manufacture. The 50,000 sq.-ft. facility has been designed to increase Upperton’s operational footprint, enabling the CDMO to support more customer projects and meet larger-scale requirements.


The facility has benefited from a significant investment in commercial scale equipment, offering powder blending up to 250kg per batch, capsule filling up to 40,000 capsules/hour, dry granulation processing up to 100kg/hour, and tablet pressing up to 120,000 tablets/hour.


Upperton will now begin the commissioning of the facility, along with the installation and validation of the new equipment. The goal is to become fully operational by 4Q23 for development and non-GMP manufacturing, with GMP operations starting in January 2024.


Nikki Whitfield, CEO of Upperton said, “We are delighted with the progress of our Nottingham facility since we first began on this journey in January 2023. This build completion is a significant milestone for us and represents our significant growth as a company. By increasing the scale at which we can operate, we are looking forward to being able to offer our customers a smooth transition from early development to clinical trials and commercial manufacturing for low volume, niche products - all at one, single site, with established project teams.”


(Source: Contract Pharma)

  • wechat
Recent Posts
  • Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    22 Oct 2024
    Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    Find out more
  • Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    20 Sep 2024
    Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    Find out more
  • AI biotechs Exscientia and Recursion agree $688m merger
    12 Aug 2024
    AI biotechs Exscientia and Recursion agree $688m merger
    Find out more

WANT TO KNOW MORE ABOUT HOW OUR

SOLUTIONS CAN HELP YOU?

Cookies
Our site uses cookies. We’d also like to set optional cookies to give you the best experience and porvide you relevant advertising. You can choose to manage your preferences or accept all cookies. You can also read our Privacy Policy and Cookie Policy for more information.